Europe's Premier End-to-End Forum for Targeted Radiopharmaceutical Development
Targeted radiopharmaceuticals have reached a defining moment. Clinical success has accelerated investment, pharma is rapidly expanding pipelines, and developers are racing to bring the next generation of alpha emitters, novel targets and precision radioligand therapies to patients.
But scientific innovation brings new challenges.
From securing isotope supply and scaling manufacturing to navigating regulation, optimising dosimetry and generating the clinical evidence needed for commercial adoption, the industry must overcome its most pressing barriers to success.
That's why 200+ leaders from pharma, biotech, regulators, clinical centres and investment will come together this December for the 8th Targeted Radiopharmaceuticals Summit Europe, the only meeting bringing together every stakeholder needed to accelerate radiopharmaceutical development from discovery through to commercialisation.
Across three days, you'll hear 50+ industry pioneers share the clinical insights, case studies and lessons learned shaping the future of targeted radiopharmaceuticals.
Benchmark your end-to-end strategy with leading organisations including Novartis, AstraZeneca, Johnson & Johnson, Bayer, Regeneron, Telix, MHRA, Swissmedic, NHS, Bicycle Tx, Ratio Tx and University Health Network, while expanding your network through interactive workshops, debates, roundtables, Q&A sessions, panel discussions, the poster session and more than 20 hours of dedicated networking.
Whether you're discovering the next breakthrough target, advancing clinical development, scaling manufacturing or preparing for commercial launch, this is where Europe's radiopharmaceutical community comes together to solve the challenges defining the next decade of RLT.
Key Focus Areas Include:
Accelerating Discovery & Preclinical Innovation
Discover how leading developers are identifying novel targets, engineering next-generation radiopharmaceutical platforms and generating the translational evidence needed to confidently progress programmes from discovery into first-in-human studies.
Advancing Clinical Translation & Earlier-Line Therapies
Learn from late-stage clinical programmes and leading treatment centres as they share strategies for optimising trial design, patient selection, dosimetry and expanding radioligand therapies into earlier lines of care and new indications.
Building Resilient CMC, Manufacturing & Isotope Supply Strategies
Explore the latest approaches to securing isotope supply, scaling GMP manufacturing, implementing automation and strengthening quality systems to support reliable clinical development and future commercial demand.
Navigating Europe's Evolving Regulatory Landscape
Hear directly from MHRA, Swissmedic, the IAEA and the Office for Nuclear Regulation on the latest regulatory expectations, licensing considerations and strategies for accelerating clinical and commercial radiopharmaceutical development across Europe.
Attending Companies Include
Where Europe's Radiopharmaceutical Community Connects to Accelerate Progress
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pharma pipelines are rapidly expanding, and next-generation alpha emitters, novel targets and precision radioligand therapies are redefining the future of oncology. As the field evolves, the industry's greatest challenge is translating innovation into scalable, clinically successful and commercially viable therapies.
From discovering differentiated targets and generating robust clinical evidence to securing isotope supply, scaling GMP manufacturing and navigating increasingly complex regulatory pathways, developers must now overcome a new generation of scientific, operational and commercial bottlenecks.
As Europe's definitive end-to-end targeted radiopharmaceuticals forum, the 8th Targeted Radiopharmaceuticals Summit Europe returns to London to unite the organisations shaping the future of radioligand therapy. Bringing together leaders across discovery, clinical development, CMC, manufacturing, isotope supply, regulatory affairs, clinical practice and investment, the 2026 programme has been designed to provide practical strategies that accelerate transformative radiopharmaceuticals from discovery to patients.
Europe's Most Comprehensive End-to-End Forum Dedicated
to Targeted Radiopharmaceutical Development
- 50+ World-Class Speakers from Across the TRP Ecosystem
- 20+ Hours of Curated Networking, Including Meet & Match Partnering
- 15+ Exclusive Clinical Readouts & Real-World Case Studies
- Brand-New Interactive Workshops & Seminars
- Europe's Strongest Regulatory Faculty (MHRA, Swissmedic, IAEA & ONR)
- The Great Isotope Debate
Explore the Agenda
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Partner With Us
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Join Europe's TRP Leaders:
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.